Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer-Reference-Cited by-同舟云学术

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer

Published:2004-12-21 Issue:1 Volume:92 Page:147-155
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Burcombe R J,Makris A,Richman P I,Daley F M,Noble S,Pittam M,Wright D,Allen S A,Dove J,Wilson G D

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6602256.pdf

Reference70 articles.

1. Akashi-Tanaka S, Tsuda H, Fukuda H, Watanabe T, Fukutomi T (1996) Prognostic value of histopathological therapeutic effects and mitotic index in locally advanced breast cancers after neoadjuvant chemotherapy. Jpn J Clin Oncol 26: 201–206

2. Allen S, Cunliffe W, Gray J, Liston J, Lunt L, Webb L, Young J (2001) Pre-operative estimation of primary breast cancer size: a comparison of clinical assessment, mammography and ultrasound. Breast 10: 299–305

3. Allred DC, Bustamante MA, Daniel CO, Gaskill HV, Cruz Jr AB (1990) Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 125: 107–113

4. Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155–168

5. Belembaogo E, Feillel V, Chollet P, Cure H, Verrelle P, Kwiatkowski F, Achard JL, Le Bouedec G, Chassagne J, Bignon YJ, De Latour M, Lafaye C, Dauplat J (1992) Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 28A: 896–900

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In-Depth Analysis of the Peripheral Immune Profile of HER2+ Breast Cancer Patients on Neoadjuvant Treatment with Chemotherapy Plus Trastuzumab Plus Pertuzumab;International Journal of Molecular Sciences;2024-08-27

2. Does immunohistochemical marker conversion affect the prognosis in breast cancer patients receiving neoadjuvant chemotherapy?;Scientific Reports;2024-06-25

3. Artificial intelligence-powered optimization of KI-67 assessment in breast cancer: enhancing precision and workflow efficiency. a literature review;Journal of the Pakistan Medical Association;2024-05-03

4. Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients;Diagnostic Pathology;2024-03-20

5. Prognostic value of receptor status conversion after neoadjuvant chemotherapy in breast cancer patients;2024-03-20